Compound Evidence File
#EC-2026-0606
Sildenafil (Viagra)
Filed under Oral Tablets. The bureau holds 111 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 3 Feb 2026 | 27 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 10.0 | 10.0 | 17 Jan 2026 | 1 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 14 Apr 2026 | 14 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 10.0 | 10.0 | 10 Mar 2026 | 2 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 26 Feb 2026 | 15 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Jan 2026 | 11 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Apr 2026 | 10 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Mar 2026 | 7 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Mar 2026 | 6 Apr 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Dec 2025 | 22 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Jan 2026 | 1 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 28 May 2026 | 27 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 10.0 | 2 Nov 2025 | 24 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 9.9 | 9.9 | 9.9 | 13 Feb 2026 | 10 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Feb 2026 | 15 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 9.9 | 9.9 | 10.0 | 27 May 2026 | 22 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Feb 2026 | 5 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 11 May 2026 | 7 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 10 May 2026 | 1 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 9 May 2026 | 28 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Jul 2026 | 21 Jul 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.9 | 8.3 | 9.6 | 21 May 2026 | 21 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.8 | 7.1 | 9.7 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.6 | 7.2 | 9.7 | 24 May 2026 | 24 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 2 | 8.5 | 7.2 | 9.8 | 21 May 2025 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 7.8 | 6.7 | 8.9 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 7.6 | 6.8 | 8.9 | 24 May 2026 | 24 May 2026 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 7.3 | 7.3 | 7.3 | 14 Jan 2025 | 14 Jan 2025 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 4 | 6.4 | 5.2 | 7.6 | 13 Feb 2025 | 20 May 2026 |
| ZhuoYan labCASE #VI-2026-0902 | X | 3 | 6.3 | 5.4 | 7.8 | 2 Apr 2025 | 25 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Jun 2025 | 13 Jun 2025 |
| HXNetCASE #VI-2026-0061 | X | 2 | 5.2 | 4.3 | 6.1 | 13 Feb 2025 | 24 May 2026 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 5.0 | 5.0 | 5.0 | 17 Dec 2024 | 17 Dec 2024 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 3.2 | 3.2 | 3.2 | 28 Mar 2025 | 28 Mar 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for Sildenafil (Viagra) alone.